Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 5 Medulloblastoma 3 Colonic Neoplasms 3 Turcot syndrome 2 Triple Negative Breast Neoplasms 2 Rhabdoid Tumor 2 Recurrence 2 Pinealoma 2 Neuroblastoma 2 Ependymoma 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Solid Tumor 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Pyloric Stenosis, Hypertrophic 1 Pancreatic Cancer Metastatic 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oropharyngeal Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Mouth Neoplasms 1 Melanoma 1 Locally Advanced Rectal Cancer 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1

Interventions

Temozolomide 42 Magnetic Resonance Spectroscopy 41 Radiotherapy 22 Specimen Handling 18 Biopsy 13 X-Rays 10 Radiation 10 trametinib 8 Bevacizumab 8 Nivolumab 7 Blood Specimen Collection 7 olaparib 6 fluorodopa F 18 6 dabrafenib 6 Radiotherapy, Intensity-Modulated 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Lomustine 6 pembrolizumab 5 abemaciclib 5 Standard of Care 5 vorasidenib 4 ulixertinib 4 larotrectinib 4 ivosidenib 4 erdafitinib 4 Surgical Procedures, Operative 4 Dianhydrogalactitol 4 Cyclophosphamide 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Celecoxib × 1 year × Clear all

NCT02115074 2026-03-18

FLUVABREX

Centre Oscar Lambret

Phase 1 Completed

Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡